Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 22 | 2024 | 297 | 4.430 |
Why?
|
| Infection Control | 15 | 2024 | 169 | 3.040 |
Why?
|
| Enterobacteriaceae Infections | 8 | 2021 | 55 | 2.240 |
Why?
|
| Klebsiella pneumoniae | 10 | 2022 | 70 | 1.900 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 5 | 2021 | 19 | 1.760 |
Why?
|
| beta-Lactamases | 12 | 2025 | 94 | 1.730 |
Why?
|
| Bacteremia | 6 | 2019 | 98 | 1.550 |
Why?
|
| Bacterial Proteins | 10 | 2025 | 89 | 1.500 |
Why?
|
| Intensive Care Units | 9 | 2024 | 247 | 1.460 |
Why?
|
| Klebsiella Infections | 9 | 2022 | 64 | 1.430 |
Why?
|
| Population Surveillance | 6 | 2018 | 106 | 1.220 |
Why?
|
| Medical Informatics | 2 | 2021 | 10 | 1.220 |
Why?
|
| Staphylococcal Infections | 4 | 2018 | 155 | 1.130 |
Why?
|
| Carrier State | 7 | 2024 | 61 | 1.040 |
Why?
|
| Clostridium Infections | 2 | 2023 | 24 | 1.010 |
Why?
|
| Humans | 51 | 2025 | 23169 | 0.910 |
Why?
|
| Public Health Surveillance | 2 | 2021 | 8 | 0.850 |
Why?
|
| Catheter-Related Infections | 3 | 2014 | 21 | 0.850 |
Why?
|
| Skin | 5 | 2025 | 119 | 0.850 |
Why?
|
| Hospitals | 12 | 2024 | 157 | 0.840 |
Why?
|
| Communicable Diseases | 1 | 2023 | 22 | 0.810 |
Why?
|
| Disease Outbreaks | 3 | 2022 | 76 | 0.770 |
Why?
|
| Virus Diseases | 1 | 2022 | 11 | 0.750 |
Why?
|
| Subacute Care | 1 | 2021 | 6 | 0.730 |
Why?
|
| Chlorhexidine | 4 | 2024 | 62 | 0.650 |
Why?
|
| Disease Notification | 2 | 2018 | 5 | 0.650 |
Why?
|
| Skilled Nursing Facilities | 5 | 2021 | 27 | 0.620 |
Why?
|
| Baths | 3 | 2024 | 30 | 0.620 |
Why?
|
| Chicago | 12 | 2024 | 816 | 0.610 |
Why?
|
| Pyomyositis | 2 | 2009 | 5 | 0.590 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2024 | 68 | 0.530 |
Why?
|
| Carbapenems | 6 | 2021 | 45 | 0.530 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 113 | 0.520 |
Why?
|
| Enterobacteriaceae | 2 | 2015 | 41 | 0.510 |
Why?
|
| Blastomycosis | 2 | 2020 | 20 | 0.460 |
Why?
|
| Illinois | 7 | 2021 | 220 | 0.460 |
Why?
|
| Hospital Information Systems | 1 | 2014 | 5 | 0.450 |
Why?
|
| Male | 22 | 2025 | 12556 | 0.420 |
Why?
|
| Health Facilities | 2 | 2024 | 26 | 0.410 |
Why?
|
| Candidiasis | 2 | 2021 | 23 | 0.410 |
Why?
|
| Patient Care | 1 | 2013 | 29 | 0.400 |
Why?
|
| Middle Aged | 17 | 2024 | 8000 | 0.400 |
Why?
|
| Community-Acquired Infections | 2 | 2012 | 66 | 0.360 |
Why?
|
| Candida | 2 | 2021 | 16 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 363 | 0.350 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 30 | 0.340 |
Why?
|
| Aged | 15 | 2025 | 7498 | 0.330 |
Why?
|
| Female | 19 | 2025 | 13059 | 0.330 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 29 | 0.330 |
Why?
|
| Ecosystem | 2 | 2021 | 24 | 0.330 |
Why?
|
| Registries | 3 | 2020 | 172 | 0.330 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 55 | 0.330 |
Why?
|
| Nursing Homes | 3 | 2025 | 41 | 0.320 |
Why?
|
| Adult | 13 | 2024 | 7031 | 0.320 |
Why?
|
| Disease Transmission, Infectious | 2 | 2021 | 19 | 0.310 |
Why?
|
| Retrospective Studies | 6 | 2023 | 3026 | 0.310 |
Why?
|
| Blastomyces | 1 | 2009 | 10 | 0.310 |
Why?
|
| Extremities | 1 | 2009 | 24 | 0.310 |
Why?
|
| Prevalence | 5 | 2018 | 384 | 0.300 |
Why?
|
| Neutropenia | 1 | 2008 | 16 | 0.290 |
Why?
|
| Public Health | 2 | 2021 | 62 | 0.290 |
Why?
|
| Anus Diseases | 1 | 2008 | 2 | 0.280 |
Why?
|
| Ulcer | 1 | 2008 | 4 | 0.280 |
Why?
|
| United States | 7 | 2023 | 1820 | 0.280 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 68 | 0.270 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 56 | 0.260 |
Why?
|
| Sepsis | 1 | 2008 | 112 | 0.250 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2024 | 47 | 0.240 |
Why?
|
| Candida glabrata | 1 | 2005 | 3 | 0.240 |
Why?
|
| Critical Illness | 2 | 2018 | 110 | 0.240 |
Why?
|
| Fungemia | 1 | 2005 | 7 | 0.240 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 27 | 0.240 |
Why?
|
| Critical Care | 2 | 2023 | 110 | 0.220 |
Why?
|
| Hospitalization | 3 | 2024 | 290 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2024 | 51 | 0.210 |
Why?
|
| Multilocus Sequence Typing | 2 | 2021 | 16 | 0.210 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.200 |
Why?
|
| Hospital Administration | 2 | 2021 | 25 | 0.200 |
Why?
|
| Long-Term Care | 4 | 2017 | 56 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 125 | 0.190 |
Why?
|
| Catheterization, Central Venous | 2 | 2014 | 35 | 0.180 |
Why?
|
| Genomics | 4 | 2023 | 51 | 0.180 |
Why?
|
| Phylogeny | 1 | 2021 | 44 | 0.180 |
Why?
|
| Computers | 1 | 2021 | 14 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 83 | 0.180 |
Why?
|
| Dermatomycoses | 1 | 2021 | 4 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2021 | 18 | 0.170 |
Why?
|
| Rectum | 5 | 2024 | 50 | 0.170 |
Why?
|
| Algorithms | 2 | 2014 | 310 | 0.170 |
Why?
|
| Clinical Protocols | 1 | 2021 | 54 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 592 | 0.170 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 14 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 53 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 201 | 0.170 |
Why?
|
| Health Personnel | 1 | 2021 | 87 | 0.160 |
Why?
|
| Otitis Media | 1 | 2020 | 3 | 0.160 |
Why?
|
| Skull Base | 1 | 2020 | 31 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 3754 | 0.150 |
Why?
|
| Quality Improvement | 2 | 2024 | 127 | 0.150 |
Why?
|
| Risk Factors | 4 | 2021 | 1988 | 0.150 |
Why?
|
| Patient Transfer | 2 | 2024 | 25 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2018 | 40 | 0.150 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 139 | 0.140 |
Why?
|
| Time Factors | 2 | 2013 | 1275 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 118 | 0.130 |
Why?
|
| Mass Screening | 1 | 2018 | 167 | 0.130 |
Why?
|
| Health Information Exchange | 1 | 2015 | 4 | 0.120 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 65 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2010 | 1425 | 0.120 |
Why?
|
| Management Audit | 1 | 2014 | 2 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 16 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2017 | 481 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 12 | 0.100 |
Why?
|
| Equipment Contamination | 1 | 2012 | 25 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2016 | 1512 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 16 | 0.090 |
Why?
|
| Bias | 1 | 2012 | 23 | 0.090 |
Why?
|
| Skin Care | 2 | 2024 | 15 | 0.090 |
Why?
|
| Ventilators, Mechanical | 2 | 2021 | 24 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2010 | 32 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 157 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2010 | 88 | 0.080 |
Why?
|
| Disease Reservoirs | 1 | 2010 | 9 | 0.080 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 8 | 0.080 |
Why?
|
| Hand Disinfection | 1 | 2010 | 25 | 0.080 |
Why?
|
| Enterococcus | 1 | 2010 | 55 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 123 | 0.080 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2009 | 1 | 0.080 |
Why?
|
| Hepatitis B Antibodies | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2009 | 12 | 0.080 |
Why?
|
| Lung Diseases, Fungal | 1 | 2009 | 10 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 29 | 0.080 |
Why?
|
| Quadriceps Muscle | 1 | 2009 | 25 | 0.080 |
Why?
|
| Adolescent | 2 | 2018 | 1916 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 7 | 0.070 |
Why?
|
| Gram-Positive Cocci | 1 | 2008 | 4 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2008 | 26 | 0.070 |
Why?
|
| Hospitals, Urban | 1 | 2008 | 34 | 0.070 |
Why?
|
| Exotoxins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Leukocidins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Prostatic Diseases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 153 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 6 | 0.070 |
Why?
|
| Sexuality | 1 | 2008 | 14 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 25 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 244 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 528 | 0.070 |
Why?
|
| Abscess | 1 | 2008 | 26 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2008 | 312 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 323 | 0.060 |
Why?
|
| Penicillanic Acid | 1 | 2005 | 3 | 0.060 |
Why?
|
| Piperacillin | 1 | 2005 | 3 | 0.060 |
Why?
|
| Fluconazole | 1 | 2005 | 7 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2016 | 113 | 0.060 |
Why?
|
| Vancomycin | 1 | 2005 | 52 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 6 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 811 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 875 | 0.060 |
Why?
|
| HIV Infections | 1 | 2009 | 424 | 0.060 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2024 | 11 | 0.060 |
Why?
|
| Animals | 1 | 2012 | 3272 | 0.060 |
Why?
|
| Bacteria | 1 | 2025 | 61 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 774 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 39 | 0.060 |
Why?
|
| Universal Precautions | 1 | 2024 | 6 | 0.050 |
Why?
|
| Iodophors | 1 | 2024 | 5 | 0.050 |
Why?
|
| California | 1 | 2024 | 35 | 0.050 |
Why?
|
| Feces | 1 | 2024 | 80 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2024 | 26 | 0.050 |
Why?
|
| Microbiota | 1 | 2025 | 65 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 33 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2024 | 146 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2023 | 6 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 8 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 43 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2023 | 40 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 449 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1048 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 8 | 0.040 |
Why?
|
| Georgia | 1 | 2021 | 12 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 18 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 77 | 0.040 |
Why?
|
| Itraconazole | 1 | 2020 | 4 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2021 | 175 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 174 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 38 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 192 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 124 | 0.040 |
Why?
|
| Integrons | 1 | 2018 | 3 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 320 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 41 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 274 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 66 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1427 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 428 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 13 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 31 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 49 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 17 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 62 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 83 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 486 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 172 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 99 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 538 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 1671 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2012 | 13 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 476 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 25 | 0.020 |
Why?
|
| Propensity Score | 1 | 2012 | 35 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 75 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2012 | 46 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 224 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 102 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1037 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2971 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 49 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2009 | 59 | 0.020 |
Why?
|